CDB-4124

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

CDB-4124
IUPAC name 17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione)
Identifiers
CAS number 136960-00-4
MeSH CDB-4124
Properties
Molecular formula C31H39NO5
Molar mass 505.65
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox disclaimer and references

WikiDoc Resources for

CDB-4124

Articles

Most recent articles on CDB-4124

Most cited articles on CDB-4124

Review articles on CDB-4124

Articles on CDB-4124 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CDB-4124

Images of CDB-4124

Photos of CDB-4124

Podcasts & MP3s on CDB-4124

Videos on CDB-4124

Evidence Based Medicine

Cochrane Collaboration on CDB-4124

Bandolier on CDB-4124

TRIP on CDB-4124

Clinical Trials

Ongoing Trials on CDB-4124 at Clinical Trials.gov

Trial results on CDB-4124

Clinical Trials on CDB-4124 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CDB-4124

NICE Guidance on CDB-4124

NHS PRODIGY Guidance

FDA on CDB-4124

CDC on CDB-4124

Books

Books on CDB-4124

News

CDB-4124 in the news

Be alerted to news on CDB-4124

News trends on CDB-4124

Commentary

Blogs on CDB-4124

Definitions

Definitions of CDB-4124

Patient Resources / Community

Patient resources on CDB-4124

Discussion groups on CDB-4124

Patient Handouts on CDB-4124

Directions to Hospitals Treating CDB-4124

Risk calculators and risk factors for CDB-4124

Healthcare Provider Resources

Symptoms of CDB-4124

Causes & Risk Factors for CDB-4124

Diagnostic studies for CDB-4124

Treatment of CDB-4124

Continuing Medical Education (CME)

CME Programs on CDB-4124

International

CDB-4124 en Espanol

CDB-4124 en Francais

Business

CDB-4124 in the Marketplace

Patents on CDB-4124

Experimental / Informatics

List of terms related to CDB-4124

CDB-4124 (Proellex™, Progenta™) is a selective progesterone receptor modulator.[1]

References

  1. Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol 88 (3): 277-88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.



WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .